Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial

Stock Trading Ideas

Trading Ideas Recent News

Top Wall Street Forecasters Revamp Core & Main Expectations Ahead Of Q2 Earnings
Top Wall Street Forecasters Revamp Core & Main Expectations Ahead Of Q2 Earnings
Core & Main reports Q2 earnings Sept. 9; analysts expect EPS to rise to 86¢ and revenue to reach $2.14B from $2.09B.
Dow Tumbles Over 600 Points Ahead of Inflation Data: Investor Sentiment Weakens, Greed Index Remains in ‘Fear’ Zone
Dow Tumbles Over 600 Points Ahead of Inflation Data: Investor Sentiment Weakens, Greed Index Remains in ‘Fear’ Zone
Market sentiment weakened as Fear & Greed fell to 40.5. U.S. stocks declined amid Middle East tensions; investors await inflation data.
Signet Jewelers, Casey's General Stores and 3 Stocks to Watch Heading Into Wednesday
Signet Jewelers, Casey's General Stores and 3 Stocks to Watch Heading Into Wednesday
Stocks in focus: Signet, American Eagle and Core & Main report; Mission Produce beats estimates; Casey’s earnings top forecasts, but shares slide.
Stock Market: Will S&P 500 Open Up or Down Today?
Stock Market: Will S&P 500 Open Up or Down Today?
Will the S&P 500 open higher? Polymarket odds rise to 66% as Wall Street weighs $99 Brent crude, Apple's product event, and upcoming CPI data.
Palantir and Nebius Team Up — Bad News for Michael Burry's Short Bets on Both Stocks
Palantir and Nebius Team Up — Bad News for Michael Burry's Short Bets on Both Stocks
Palantir names Nebius its preferred sovereign AI partner, boosting Nebius shares as both companies challenge Michael Burry’s bearish bets.
Nancy Pelosi Bought the Dip on Bloom Energy Stock: Gains are 7x Congressional Salary in Two Months
Nancy Pelosi Bought the Dip on Bloom Energy Stock: Gains are 7x Congressional Salary in Two Months
One of Nancy Pelosi's newest stock pick is already up millions of dollars.
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
Why Oracle Stock is the Trade to Watch After OpenAI's AGI Claim
Why Oracle Stock is the Trade to Watch After OpenAI's AGI Claim
Oracle's $300 billion OpenAI deal makes it an AGI infrastructure proxy. Thursday's earnings will test cloud growth and backlog conversion.
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
Stock of the Day: Is This the Bottom for Fair Issac?
Stock of the Day: Is This the Bottom for Fair Issac?
Fair Isaac is oversold and near $920 support after a 17% drop, suggesting a potential rebound as buyers may drive shares higher.
Why Guidewire Stock Dropped After Reporting An Upbeat Quarter
Why Guidewire Stock Dropped After Reporting An Upbeat Quarter
The Guidewire stock drop hit 20% after a Q4 earnings beat. See why soft FY27 guidance and a stretched valuation triggered the sell-off.
Netflix Faces South Africa Price Probe, Putting Stock Under Pressure
Netflix Faces South Africa Price Probe, Putting Stock Under Pressure
Netflix stock dips over 2% following market softness and news that South African regulators are investigating consumer costs for digital streaming services.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved